Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02693535 · ClinicalTrials.gov registry record · Phase 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

A Phase 2 study of Multiple Myeloma and Advanced Solid Tumors, sponsored by American Society of Clinical Oncology.

Recruiting
Registry status
Phase 2
Development phase
4,200
Enrollment target
20
Study locations

NCT02693535: Recruiting Phase 2 study of Multiple Myeloma and Advanced Solid Tumors, sponsored by American Society of Clinical Oncology.

NCT02693535 is a Phase 2 study of Multiple Myeloma and Advanced Solid Tumors that is actively recruiting participants, run by American Society of Clinical Oncology. The registered enrollment target is 4,200 participants, above the 537-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (682% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02693535, a Phase 2 study of Multiple Myeloma and Advanced Solid Tumors, is actively recruiting participants, sponsored by American Society of Clinical Oncology.

RECRUITING
Registry status
Phase 2
Development phase
4,200 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Primary Outcome

Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.

Conditions Studied

Multiple Myeloma Advanced Solid Tumors Lymphoma, Non-Hodgkin

Interventions

  • DRUG Sunitinib
  • DRUG Palbociclib
  • DRUG Temsirolimus
  • DRUG Trastuzumab and Pertuzumab
  • DRUG Vemurafenib and Cobimetinib

Study Locations (20)

California

  • Sutter Auburn - Auburn
  • Sutter Alta Bates - Berkeley
  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate - Los Angeles
  • Kaiser Permanente - Oakland Medical Center - Oakland
  • Sutter Palo Alto Medical Foundation: Palo Alto - Palo Alto
  • Kaiser Permanente - Roseville Medical Center - Roseville
  • Sutter Roseville - Roseville
  • Kaiser Permanente - Sacramento Medical Center - Sacramento
  • Sutter Sacramento - Sacramento
  • Kaiser Permanente - South San Francisco Medical Center - San Francisco
  • California Pacific Medical Center Research Institute - San Francisco
  • Kaiser Permanente - San Francisco Medical Center - San Francisco
  • Sutter Cancer Research Consortium - San Francisco
  • Kaiser Permanente - San Jose Medical Center - San Jose
  • Kaiser Permanente - San Leandro Medical Center - San Leandro
  • Kaiser Permanente - Santa Clara Medical Center - Santa Clara
  • Sutter Palo Alto Medical Foundation: Santa Cruz - Santa Cruz
  • Sutter Palo Alto Medical Foundation: Fremont - Santa Cruz

Alabama

  • University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham

Arizona

  • Cancer Treatment Centers of America-Phoenix - Phoenix

Trial Details

FieldValue
Enrollment Target 4,200 participants
Start Date 2016-03-14
Est. Completion 2028-12-31
Phase Phase 2
American Society of Clinical Oncology

2 total trials

What NCT02693535 shows while recruiting

NCT02693535 is an interventional study that assigns participants to a tested intervention. Its 4,200 participants enrollment target places it among the larger protocols in the corpus, above the 537-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (682% higher).

The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Sunitinib is the first listed.

NCT02693535 names 20 study sites across 3 states, led by California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT02693535 about?

NCT02693535 is a clinical study titled "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer". The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include ...

What is the current status of trial NCT02693535?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 4,200 participants. The study started on 2016-03-14. Estimated completion is 2028-12-31.

What conditions does trial NCT02693535 study?

This clinical trial studies the following conditions: Multiple Myeloma, Advanced Solid Tumors, Lymphoma, Non-Hodgkin.

What interventions are being tested in trial NCT02693535?

The interventions under investigation include: Sunitinib (DRUG), Palbociclib (DRUG), Temsirolimus (DRUG), Trastuzumab and Pertuzumab (DRUG), Vemurafenib and Cobimetinib (DRUG).

Who is sponsoring clinical trial NCT02693535?

This trial is sponsored by American Society of Clinical Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02693535 being conducted?

This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02693535's enrollment target sits among peer trials

4,200 8th of 438 higher than 431 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05969028 · 4,200 participants · NA

    First Responder Airway & Compression Rate Trial

  • NCT06935370 · 4,200 participants · Phase 3

    A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  • NCT07209098 · 4,200 participants

    Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure

  • NCT06492616 · 4,220 participants · Phase 3

    A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT02693535

Source: ClinicalTrials.gov NCT02693535, the US trial registry maintained by the National Library of Medicine. NCT02693535 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.